title: Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism.
abstract: Angiotensin II, when given in low doses, raises blood pressure slowly. When tested in vitro on vascular smooth muscle cells, it has mitogenic and trophic effects; it is not known if it has these effects in vivo. Our purpose was to determine whether vascular hypertrophy develops during slow pressor infusion of angiotensin II and, if so, whether it is pressure induced. Three experiments were done in rats infused subcutaneously with angiotensin II (200 ng/kg/min) by minipump for 10-12 days. Experiment 1: Angiotensin II gradually raised systolic blood pressure (measured in the tail) from 143 +/- 2 to 208 +/- 8 mm Hg (mean +/- SEM), significantly suppressing plasma renin and increasing threefold (NS) plasma angiotensin II. There was no loss of peptide in the pump infusate when tested at the end of the experiment. Experiment 2: In the perfused mesenteric circulation, vasoconstrictor responses to norepinephrine, vasopressin, and KCl were enhanced in rats given a slow pressor infusion of angiotensin II, but sensitivity of responses was not altered. This combination of changes suggests that vascular hypertrophy develops during slow pressor infusion of angiotensin II. Experiment 3: Vessel myography was done after angiotensin II infusion with and without a pressor response. Angiotensin II raised systolic blood pressure, increased heart weight, and produced myographic changes of vascular hypertrophy in the mesenteric circulation, increasing media width, media cross-sectional area, and media/lumen ratio. Hydralazine given with angiotensin II prevented the rise of pressure and the cardiac effect but not the vascular changes. Two-way analysis of variance showed that angiotensin II significantly increased media width, media cross-sectional area, and media/lumen ratio, all independent of hydralazine. Thus, although hydralazine inhibits the pressor and cardiac effects of angiotensin II, suggesting a pressor mechanism for the cardiac change, it does not inhibit structural vascular change, which suggests that at least part of the effect has a non-pressor mechanism.
authors.affiliation: MRC Blood Pressure Unit, Western Infirmary, Glasgow, Scotland.
authors.forename: S A
authors.initials: SA
authors.lastname: Griffin
authors.forename: W C
authors.initials: WC
authors.lastname: Brown
authors.forename: F
authors.initials: F
authors.lastname: MacPherson
authors.forename: J C
authors.initials: JC
authors.lastname: McGrath
authors.forename: V G
authors.initials: VG
authors.lastname: Wilson
authors.forename: N
authors.initials: N
authors.lastname: Korsgaard
authors.forename: M J
authors.initials: MJ
authors.lastname: Mulvany
authors.forename: A F
authors.initials: AF
authors.lastname: Lever
mesh_terms: D000804:Angiotensin II / Q000097:blood / Q000494:pharmacology*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D001808:Blood Vessels / Q000187:drug effects* / Q000473:pathology; D006984:Hypertrophy; D007260:Infusion Pumps; D007279:Injections, Subcutaneous; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D012083:Renin / Q000097:blood; D013152:Splanchnic Circulation / Q000187:drug effects; D013599:Systole
chemical_list: D000804:Angiotensin II; D012083:Renin